<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04216004</url>
  </required_header>
  <id_info>
    <org_study_id>20173</org_study_id>
    <nct_id>NCT04216004</nct_id>
  </id_info>
  <brief_title>Anti-Inflammatory Milk Matrix</brief_title>
  <acronym>AIMM</acronym>
  <official_title>Dairy Food Consumption and Its Effects on Inflammation and the Postprandial Regulation of Muscle Protein Synthesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Urbana-Champaign</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Illinois at Urbana-Champaign</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is pro-inflammatory, impairs metabolism, and physically limiting. Specifically,&#xD;
      muscle in obese persons does not synthesize proteins normally. This further increases&#xD;
      metabolic and physical dysfunction. As such, obesity programs should not only focus on weight&#xD;
      loss, but muscle metabolic health. Dairy nutrients have anti-inflammatory and anabolic&#xD;
      properties, but mostly evaluated in isolation and/or pre-clinical designs. Also, it is&#xD;
      unknown if the circulating benefits extend to the muscle. We hypothesize that dairy full-fat&#xD;
      milk will improve these obesity characteristics.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fractional synthetic rate of myofibrillar proteins by stable isotope infusion.</measure>
    <time_frame>0-5 hours postprandial observation period to ingesting 2 servings of respective Arm.</time_frame>
    <description>Refers to rate of building new proteins in skeletal muscle contractile protein fraction. Myofibrillar protein synthesis rates will be assessed during stable isotope infusion whereby participants will ingest 2 servings of their respective dairy treatment and the postprandial response is compared between the Arms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood inflammation markers by flow cytometry.</measure>
    <time_frame>1 week observation period to respective Arm within a controlled-feeding intervention.</time_frame>
    <description>Measurement of blood cytokines, monocytes, and macrophages by flow cytometry before and after 1-week of 3 daily servings of respective dairy treatment within a controlled-feeding intervention.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Obesity</condition>
  <condition>Skeletal Muscle</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Full-fat dairy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3x daily servings (cup-eq) of full-fat (3.25%) commercial cow's milk.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-fat diary</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3x daily servings (cup-eq) of non-fat (0%) commercial cow's milk.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-dairy control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3x daily servings (cup-eq) of non-dairy sourced macronutrient composition of full-fat milk.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Controlled-Feeding Intervention</intervention_name>
    <description>All energy-containing food and beverages will be provided for 1-week as a controlled-feeding study.</description>
    <arm_group_label>Full-fat dairy</arm_group_label>
    <arm_group_label>Non-dairy control</arm_group_label>
    <arm_group_label>Non-fat diary</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Non-dairy beverage</intervention_name>
    <description>Isolated amino acid, fatty acid, and monosaccharide beverage matched to the macronutrient content of 8 fl oz whole milk.</description>
    <arm_group_label>Non-dairy control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Full-fat milk</intervention_name>
    <description>3 daily servings (cup-eq) of full-fat (3.25%) commercial cow's milk.</description>
    <arm_group_label>Full-fat dairy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fat-free milk</intervention_name>
    <description>3 daily servings (cup-eq) of fat-free (0%) commercial cow's milk.</description>
    <arm_group_label>Non-fat diary</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Obese (BMI, body mass index ≥30, &lt;40 kg•m-2)&#xD;
&#xD;
          -  Age 40-59&#xD;
&#xD;
          -  Pre-menopausal&#xD;
&#xD;
          -  Sedentary/insufficiently active for prior 6 months (mo)&#xD;
&#xD;
          -  Weight stable for prior 6 mo&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tobacco, nicotine (patch/gum) use (previous 6 mo)&#xD;
&#xD;
          -  Alcohol consumption &gt;10 drinks per week&#xD;
&#xD;
          -  Metabolic disorders (e.g., Metabolic Syndrome, Diabetes, thyroid diseases)&#xD;
&#xD;
          -  Cardiovascular disease, arrhythmias&#xD;
&#xD;
          -  Hypogonadism&#xD;
&#xD;
          -  Asthma&#xD;
&#xD;
          -  History of uncontrolled hypertension&#xD;
&#xD;
          -  Orthopedic injury/surgery (within 1 yr)&#xD;
&#xD;
          -  Hepatorenal, musculoskeletal, autoimmune, or neurological disease&#xD;
&#xD;
          -  History of neuromuscular problems&#xD;
&#xD;
          -  Previous participation in amino acid tracer studies&#xD;
&#xD;
          -  Predisposition to hypertrophic scarring or keloid formation&#xD;
&#xD;
          -  Consumption of ergogenic-levels of dietary supplements that may affect muscle mass&#xD;
             (e.g., creatine, HMB), insulin-like substances, or anabolic/catabolic pro-hormones&#xD;
             (e.g., DHEA) within 6 weeks prior to participation&#xD;
&#xD;
          -  Consumption of thyroid, androgenic, or other medications known to affect endocrine&#xD;
             function&#xD;
&#xD;
          -  Consumption of medications known to affect protein metabolism (e.g.,&#xD;
             prescription-strength corticosteroids, non-steroidal anti-inflammatories, or acne&#xD;
             medication)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Allergy to dairy product or lactose intolerance&#xD;
&#xD;
          -  Fasting plasma glucose (FPG) ≥ 126 mg/dL&#xD;
&#xD;
          -  Oral glucose tolerance test (OGTT) ≥ 200 mg/dL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicholas A Burd, Ph.D.</last_name>
    <phone>217-244-0970</phone>
    <email>naburd@illinois.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Freer Hall</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas A Burd, Ph.D.</last_name>
      <phone>217-244-0970</phone>
      <email>naburd@illinois.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>December 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Urbana-Champaign</investigator_affiliation>
    <investigator_full_name>Nicholas Burd</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

